DAWN NASDAQ
Brisbane, CA 94080
US
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AI Day1 LLC | U-Tender | 12,929,322 | $21.50 | 2026-04-23 |
| Bender Jeremy | D-Return | 286,000 | $8.99 | 2026-04-23 |
| Bender Jeremy | D-Return | 355,000 | $11.16 | 2026-04-23 |
| Bender Jeremy | D-Return | 222,188 | — | 2026-04-23 |
| VASCONCELLES MICHAEL | D-Return | 346,000 | $6.64 | 2026-04-23 |